WASHINGTON (Reuters Health) – Switzerland's Roche Holding AG issued a statement Wednesday clarifying that the company's recently disclosed production problems would only affect the pediatric version of its influenza therapy Tamiflu (oseltamivir).
On January 10, Roche announced that an equipment problem would delay shipments of the oral suspension. Roche said that the problem was unrelated to the drug and would be fixed in a matter of weeks.
According to Roche, certain media outlets subsequently reported that Tamiflu would not be available for the 2002 to 2003 flu season. Roche said that these reports were false and that these media outlets have been asked to issue a correction. Roche said that the Tamiflu capsules were unaffected by the production problem and remain available nationwide.
The Tamiflu capsules are indicated for the treatment of adults and adolescents over the age of 13, as well as children weighing more than 88 pounds.
In earlier interview with Reuters, the company added that the oral suspension represented a small fraction of Tamiflu sales and that the production problem would only delay shipments in the US.